The USBC, Inc. (NYSE American: USBC) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures, along with AI-powered summaries that help explain complex documents in plain language. USBC is a Nevada-incorporated, publicly traded, multi-disciplinary technology company that focuses on digital financial technologies, including tokenized U.S. dollar deposits and a Bitcoin treasury strategy, as well as non-invasive health monitoring research.
Through its registration statements on Form S-1 and S-1/A, USBC outlines its business overview, corporate history, and strategic transition from its legacy non-invasive sensor technology operations as Know Labs, Inc. to a broader financial technology platform. These filings describe the USBC tokenized deposit offering, a U.S.-dollar denominated tokenized representation of a bank deposit account that operates on blockchain technology and is embedded with digital identity, and detail the establishment of a Bitcoin treasury as a primary reserve asset.
Current and prospective investors can review USBC’s Forms 8-K for information on material events, including the strategic investment by Goldeneye 1995 LLC, changes to its equity incentive plans, executive departures and related separation agreements, option repricing and new equity grants, and amendments to digital asset management agreements for its Bitcoin treasury strategy. These filings also document the company’s name and ticker change to USBC, Inc. and “USBC” on the NYSE American.
On Stock Titan, AI-generated insights highlight key sections of USBC’s filings, such as risk factor discussions, descriptions of the tokenized deposit model and Bitcoin treasury program, and details of significant capital transactions. Users can also track updates related to equity compensation plans and governance decisions reported under Item 5.02 of Form 8-K. Real-time integration with EDGAR helps ensure that new USBC filings, including future annual reports on Form 10-K, quarterly reports on Form 10-Q, and additional 8-Ks, are quickly available with concise explanations of their main points.
Amendment No. 1 to Schedule 13D reports that Robert Gregory Kidd and Goldeneye 1995 LLC hold an aggregate of 357,815,000 shares of USBC, Inc. common stock, representing approximately 92.1% of the 388,143,679 shares outstanding as of September 15, 2025. The filing states Mr. Kidd and Goldeneye each have sole voting and dispositive power over these shares. On September 19, 2025 the parties entered into a Registration Rights Agreement and the issuer filed a Form S-1 covering resale of the shares issued to Goldeneye in the private placement. No other transactions in the prior 60 days were reported.
USBC, Inc. is registering 367,634,098 shares of common stock for resale by existing stockholders, including shares issued in a large August 2025 private placement and related advisor and consultant compensation. USBC will not receive any proceeds from these resale transactions.
As of September 15, 2025, USBC had 388,143,679 shares of common stock outstanding. The company has strategically shifted from solely sensor technology toward a multi‑disciplinary model combining non‑invasive medical technology with digital‑asset and banking initiatives, including a Bitcoin treasury of about 1,000 Bitcoin and development of the USBC token. USBC also maintains an at‑the‑market equity program under a separate Form S‑3 shelf, with up to $14.5 million of stock available for sale through JonesTrading.
USCB Financial Holdings is updating its at-the-market stock offering program, allowing it to offer and sell shares of common stock with an aggregate offering price of up to $14,500,000 through JonesTrading Institutional Services under an existing sales agreement. The company states that its public float is now above $75.0 million, so it is no longer subject to the Form S-3 General Instruction I.B.6 sales limitations for this registration. As of September 2, 2025, public float was $87,168,697, based on 23,622,953 shares held by non-affiliates at a price of $3.69 per share, the closing price on July 8, 2025. The common stock trades on the NYSE American under the symbol USBC, and the last reported sale price on September 4, 2025 was $0.74 per share.
USBC, Inc. entered into a Capital on Demand at-the-market equity program with JonesTrading that originally allowed sales of up to $5,000,000 of common stock. The company has now increased the amount available for sale under this Sales Agreement to an aggregate offering price of up to $14,500,000, using its already effective $18,000,000 shelf registration on Form S-3.
There is no minimum sale requirement, so the actual number of shares sold and total proceeds will depend on future market transactions. USBC plans to use any net proceeds primarily for general corporate purposes, including working capital and capital expenditures. Since December 31, 2024, the company has sold 1,708,124 shares under the program for gross proceeds of approximately $1,269,236, and common shares outstanding were 384,234,130 as of September 4, 2025.
USBC, Inc. discloses portions of its definitive proxy statement including director background, related-party professional fees and governance procedures. The filing states that Mr. Cronin holds multiple engineering degrees and a B.A. in Psychology from the University of Vermont. The company reports it paid ipCG approximately $390,000 for the year ended September 30, 2024 and $713,000 for the year ended September 30, 2023 in professional fees. It also states Mr. Cronin is not considered an independent director because of prior service as Interim Chief Technology Officer from September 2024 to August 2025. The document includes placeholders for compensation components such as base salary, stock options, benefits and accrued vacation pay and restates proxy submission requirements for shareholder proposals.